Krónikus vesebetegség: vizsgálatok itt: Japán
11 of 14 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in JapánA Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Where
- Aichi, Arakawa-ku, Tokyo, Chiba-shi, Chiba, Chikushino-shi, Fukuoka, Gifu, Ibaraki, Kamakura-shi, Kanagawa, Koriyama-shi, Fukushima, Minato-ku, Tokyo, Mito-shi, Ibaraki, Oita-shi, Oita,, Sendai, Miyagi, Tamana-shi, Kumamoto, Tokyo, Tsu-shi, Mie, Wakayama
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07931547 · EU 2026-525471-13-00 - 3. fázisTaking peopleA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- Where
- Aira, Amagasaki-shi, Beppu-shi, Chigasaki-shi, Fujinomiya-shi, Hakodate-shi, Hamamatsu, Higashihiroshima-shi, Iizuka-shi, Inashiki-gun, Iwata-shi, Kagoshima, Kamakura-shi, Kanazawa, Kashiwara-shi, Kasugai-shi, Kita-ku, Kitakyushu, Kitakyushu-shi, Kobe, Kumagaya-shi, Kurashiki-shi, Kuse-gun, Kuwana-shi, Kyoto, Matsusaka-shi, Matsuyama, Meguro-ku, Minatoku, Minokamo Shi, Miyakonojo-shi, Morioka, Nagaoka-shi, Naka, Narita-shi, Obihiro-shi, Ōita, Ōme, Ōmihachiman, Osaka, Saga, Sapporo, Sendai, Shibuya-ku, tabashi City, Tanabe-shi, Toyoake-shi, Toyohashi, Tsu, Yaizu-shi, Yokohama, Yoshida-gun
- Életkor
- 18 év and over
- People
- 5000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06742723 · EU 2023-506460-14-00 - 3. fázisTaking peopleA Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Where
- Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka, Uji, Wakayama
- Életkor
- 50 év and over
- People
- 7140 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07241390 · EU 2025-523123-22-00 - 2. fázisTaking peopleDose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
- Where
- Kamakura, Kasugai, Matsubara, Matsudo
- Életkor
- 18 év to 80 év
- People
- 180 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07830719 · EU 2026-525974-21-00 - 3. fázisFut, nem toborozA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Chiba, Kasugai, Kawasaki, Kyoto, Matsumoto, Niigata, Okayama, Ōmihachiman, Osaka, Sapporo, Sendai, Toyoake, Toyota, Yokohama
- Életkor
- 18 év to 100 év
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - 3. fázisTaking peopleA Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
- Where
- Ageo, Asahi-shi, Chiba, Fukaya, Fukui-shi, Izumisano, Izunokuni-shi, Kariya, Kisarazu-shi, Kita-ku, Kitakyusyu-shi, Kofu, Koga-shi, Komatsu-shi, Koshigaya-shi, Kumagaya-shi, Kumamoto, Kurashiki-shi, Kuwana-shi, Kyoto, Matsumoto-shi, Minamiuonuma, Minatoku, Minokamo Shi, Morioka, Nagoya, Naka, Nerima-ku, Osaka, Sendai, Takatsuki-shi, Toride-shi, Tsu, Urayasu, Yokohama
- Életkor
- 18 év to 99 év
- People
- 2800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07624305 · EU 2026-526114-90-00 - 2/3. fázisTaking peopleCombined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Where
- Hashima-gun, Higashiosaka-shi, Hiroshima, Hokkaido, Ibaraki, Ichinomiya-shi, Inashiki-gun, Kagoshima, Kamakura-shi, Kanazawa, Kitakyushu-shi, Kurume, Kurume-shi, Kusatsu-shi, Kyoto, Maebashi, Matsubara-shi, Nagaoka-Shi, Nagoya, Ogaki-Shi, Ōmihachiman, Oyama-shi, Sakaimachi, Sapporo, Shinjuku-Ku, Takasaki-Shi, Tsukuba, Ube-shi, Urayasu-shi, Yamagata, Yokohama, Yonago-shi
- Életkor
- 18 év and over
- People
- 3110 worldwide
- Run by
- CSL Behring
See details and how to joinNCT05485961 · EU 2022-500273-14-00 - 3. fázisTaking peopleA Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Where
- Aira, Akita, Asahikawa-shi, Chūōku, Fujisawa-shi, Fukuoka, Hachioji-shi, Hamamatsu, Hiroshima, Ichikawa-shi, Ina-shi, Iruma-Gun, Izunokuni-shi, Kamakura-shi, Kamiina-gun, Kanazawa, Kasugai-shi, Kasuga-shi, Kawachinagano-shi, Kitakyushu, Kitakyushu-shi, Kumamoto, Kurume, Kuwana-shi, Matsumoto-shi, Minatoku, Minokamo Shi, Moriyama-shi, Nagoya, Naka, Ōita, Okayama, Osaka, Oyama-shi, Sakaishi, Sakushu, Sapporo, Sasebo-shi, Shinjuku-ku, Suita-shi, Suwa-shi, Takasago-shi, Tsu, Ueda-shi, Ushiku-shi, Utsunomiya, Yokohama
- Életkor
- 18 év and over
- People
- 7000 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07753993 · EU 2025-523994-41-00 - 3. fázisTaking peopleA Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
- Where
- Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi, Nagoya, Osaka, Sapporo, Suita-shi, Tachikawa-shi, Toyota-Shi
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07662135 · EU 2025-523940-12-00 - 1. fázisTaking peopleA Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus
- Where
- Fukuoka
- Életkor
- 18 év to 64 év
- People
- 120
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07619157 - 2. fázisTaking peopleA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
- Where
- Aichi, Ibaraki, Kanagawa, Kita-ku, Tokyo, Koriyama-shi, Fukushima, Saitama, Sendai-shi, Miyagi, Siga, Tokyo
- Életkor
- 18 év and over
- People
- 465 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06717698 · EU 2024-510846-15-00